Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.38M 2.22M 2.04M 3.83M 265M 3.9M 26.21M 10.26M 133M 10.41M 10.19M 440M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.51M 7.95M 7.29M 13.72M 949M 13.94M 93.82M 36.74M 476M 37.27M 36.46M 1.57B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 77 30/11/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%+2.37%+69.11%+110.88% 73.45B
+0.87%+17.17%+53.05%+95.59% 62.99B
+1.71%-1.44%+2.66%+501.29% 28.05B
-1.40%+4.18%+54.52%+19.60% 25.42B
+21.96%+21.90%+0.51%+2.50% 23.3B
+2.28%+7.98%+42.75%-12.34% 19.45B
0.00%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+17.17%+534.55% 16.53B
+2.39%+5.96%+44.04%+157.77% 13.16B
Average +2.49%+2.74%+58.64%+203.74% 31.17B
Weighted average by Cap. +1.63%+4.39%+57.10%+168.10%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.99 0.1 0.69 0.27 3.5 0.27 0.27 11.59 0.14 0.12 0.11 0.1 0.19 12.94 0.19 1.28 0.5 6.49 0.51 0.5 21.45
Net income -3.1M -2.66M -2.49M -2.28M -4.29M -297M -4.36M -29.35M -11.49M -149M -11.66M -11.4M -492M -18.47M -15.85M -14.8M -13.58M -25.53M -1.77B -25.95M -175M -68.38M -886M -69.37M -67.86M -2.93B
Net Debt 7.1M 6.09M 5.68M 5.21M 9.81M 678M 9.97M 67.06M 26.26M 340M 26.64M 26.06M 1.12B 7.15M 6.14M 5.73M 5.26M 9.89M 684M 10.05M 67.61M 26.47M 343M 26.86M 26.27M 1.13B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-